INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
INSPIRE
2 other identifiers
interventional
2,748
1 country
3
Brief Summary
The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable breast-cancer
Started Sep 2026
Typical duration for not_applicable breast-cancer
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 22, 2026
CompletedFirst Posted
Study publicly available on registry
June 26, 2026
CompletedStudy Start
First participant enrolled
September 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2031
July 2, 2026
June 1, 2026
3.8 years
June 22, 2026
June 30, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Treatment modifications
Any dose reduction or delay during treatment.
Tumor board presentation to 3 months
Secondary Outcomes (28)
Treatment Modifications (2)
Tumor board presentation to 6 months
Symptom Experience
Tumor board to 6 months
Symptom Experience (1)
Tumor board to 3 months
Treatment alignment
Tumor board presentation to 3 months
Treatment Intensity
Tumor board presentation to 3 months
- +23 more secondary outcomes
Other Outcomes (4)
Tumor board context
During tumor board discussion
Fitness discussed
During tumor board and/or initial clinic note
Preferences Discussed
during tumor board and/or initial clinic note
- +1 more other outcomes
Study Arms (3)
Group A- Enhanced Usual Care
ACTIVE COMPARATORPatient-reported outcomes captured; no data presented in any multidisciplinary tumor board. This group is a historical control.
Group B- Enhanced Clinician Awareness
ACTIVE COMPARATORPatient-reported outcomes (PROs) captured with no personal data presented to multidisciplinary tumor board; other patient's PROs may be presented. This groups is a contemporary control.
Group C- INSPIRE intervention
EXPERIMENTALPatient-reported outcomes presented to multidisciplinary tumor board
Interventions
The INSPIRE intervention is the systematic capture and presentation of patient-reported outcomes (geriatric assessment, patient preferences, and distance to care) within multi-disciplinary tumor boards
Capture of patient-reported outcomes including geriatric assessment and patient preferences
Inclusion of patients within tumor board that may have patient-reported outcomes
Eligibility Criteria
You may not qualify if:
- aged 18 years or older;
- with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis;
- intention to be treated at a participating institution;
- with verbal fluency in English or Spanish; and
- scheduled to be discussed at MDTB.
- All clinical team members participating in the pancreatic, breast, or gynecologic MDTB at a participating site will be included and have pre-emptively agreed to participation.
- Individuals with plans to receive cancer treatment outside the participating institution and inability to speak English or Spanish.
- Clinicians will retain the opportunity to opt-out of participation, in which case their portions of the discussion will not be included in the analysis; however, this is not anticipated based on pilot data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Alabama at Birminghamlead
- University of Oklahomacollaborator
- University of California, Los Angelescollaborator
- Canopy Cancer Collective, LLCcollaborator
Study Sites (3)
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
University of California Los Angeles (UCLA)
Los Angeles, California, 90404, United States
University of Oklahoma (OU) Health Campus
Oklahoma City, Oklahoma, 73126-0901, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gabrielle B Rocque, MD
The University of Alabama at Birmingham
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
June 22, 2026
First Posted
June 26, 2026
Study Start
September 1, 2026
Primary Completion (Estimated)
July 1, 2030
Study Completion (Estimated)
July 1, 2031
Last Updated
July 2, 2026
Record last verified: 2026-06